Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28659623 | 0.89 | CYP19A1 (0.32) | ACHE | |
| SCHEMBL31712990 | 0.89 | — | — | |
| SCHEMBL29550114 | 0.81 | — | — | |
| SCHEMBL157325 | 0.81 | — | — | |
| SCHEMBL31043123 | 0.79 | — | — | |
| SCHEMBL1819400 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL31159090 | 0.79 | ALDH1A1 (0.35) | ACHECYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29651204 | 0.79 | ALDH1A1 (0.35) | ACHECYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27985804 | 0.79 | ALDH1A1 (0.35) | ACHECYP1A2SMN1; SMN2 | |
| SCHEMBL30099072 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | claimed |
| US-9233980-B2 | Process for preparing a compound by a novel sandmeyer-like reaction using a nitroxide radical compound as a reaction catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | disclosed |
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1592689-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ACHE 1454/4885CYP1A2 1351/4885SMN1; SMN2 4201/4885 |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | TYR, NOX5, NOXO1 | ACHE 936/4885CYP1A2 1493/4885SMN1; SMN2 3290/4885 |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | ACHE 3194/4885CYP1A2 1124/4885SMN1; SMN2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.